Nexalin Technology, Inc. (NXL): Cost of Revenue

Annual figures by period end, from SEC filings.

$61.4K

Year ended 2025-12-31

$30.1K

Trailing 12 months to 2026-06-30

-44.7%

3-year compound annual growth

2021-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$61.4K	+67.7%	2026-03-25, From 2025-01-01
2024-12-31	$36.6K	+42.5%	2026-03-25, From 2024-01-01
2023-12-31	$25.7K	-92.9%	2025-09-23, From 2023-01-01
2022-12-31	$363.2K	n/m	2024-03-27, From 2022-01-01
2021-12-31	$21.4K	n/a	2023-03-27, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Nexalin Technology, Inc. (NXL)	2025-12-31	$61.4K	+67.7%
Positron Corp (POSC)	2025-12-31	$2.58M	+177.1%
iTonic Holdings Ltd (ITOC)	2025-12-31	$195.7K	+191.9%
Guided Therapeutics Inc (GTHP)	2025-12-31	$196.0K	n/m
Hongchang International Co., Ltd (HCIL)	2024-12-31	$2.69M	+3.0%
ADM Tronics Unlimited, Inc. (ADMT)	2026-03-31	$1.99M	+10.6%
Neuraxis, Inc (NRXS)	2025-12-31	$562.9K	+55.5%
Yubo International Biotech Ltd (YBGJ)	2025-12-31	$4.2K	+409.5%
Nuwellis, Inc. (NUWE)	2025-12-31	$3.15M	+2.7%

Compare NXL, POSC, ITOC, GTHP side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗